Navigation Links
China's Rheumatoid Arthritis Drug Market Will More than Double by 2013

WALTHAM, Mass., July 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis (RA) drug market will more than double by 2013, growing from $138 million in 2008 to $385 million in 2013. This growth will be fueled by a growing drug-treated population, increasing patient access to healthcare insurance, greater patient spending power and increased use of biological agents in RA treatment.

"A principal driver of growth in the Chinese RA market is the expanding patient population. We expect the number of patients eligible for drug therapy to increase 52 percent by 2013. During the same 2008-2013 time period, the drug-treated population will grow approximately 80 percent," stated Jing Wu, M.S., MBA.

The new Emerging Markets report entitled Rheumatoid Arthritis in China also finds that Western branded drug sales will command 54 percent of the market by 2013. The key drivers of this growth will be the increased uptake of currently available Western branded biologics and the launch of new biologics. The best opportunities for Western drug companies are in the launch and marketing of new biological agents that are easily administered and have novel mechanisms of action that achieve quicker onset of disease-modifying activity.

"We expect less competition from Chinese generic versions of new Western branded biologics than for small-molecule drugs for two reasons: biologics are harder to imitate than small chemical molecules and it is difficult to convince physicians that biosimilars have the same activity as the original brands," added Ms. Wu.

The report contains primary research of physicians and epidemiology study in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou and Jinan.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                 Elizabeth Marshall
    Decision Resources               Decision Resources, Inc.
    781-296-2691                     781-296-2563

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
2. New Drug Promising Against Rheumatoid Arthritis
3. Over half of people with rheumatoid arthritis have periodontitis
4. Exercise improves functional and psycological ability and reduces steroid need in rheumatoid arthritis
5. Rheumatoid arthritis is associated with poor sleep in women
6. Rheumatoid Arthritis Drug Might Fight Swine Flu
7. Treating gum disease helps rheumatoid arthritis sufferers
8. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
9. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
10. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
11. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
Breaking Medicine Technology: